Immunovant, Inc.
NASDAQImmunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the other. The options market is the loudest signal this week. The put/call ratio has collapsed to 0.05, the lowest reading of the past year and nearly three standard…
Snapshot as of 20 May 2026
Immunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the…
Immunovant is heading into its May 29 earnings event carrying a sharply split set of signals — an unusually bullish options print colliding with a stubborn double-digit short position and a month of executive…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMVT — free to start on ORTEX.
Sign up for free →Open IMVT on ORTEX